News

ISS A/S Share Buyback Program Enhances Shareholder Value

ISS A/S Share Buyback Program Enhances Shareholder Value

Key Insights into ISS A/S's Share Buyback Program

ISS A/S, renowned for its excellence in workplace experience and facility management, has launched an ambitious share buyback initiative aimed at enhancing shareholder value. This program was officially announced on 20 February 2025, laying a solid foundation for the company's commitment to returning excess cash to its investors. By adhering to the Market Abuse Regulation guidelines, ISS is not only maintaining transparency but also reinforcing trust with its stakeholders.

Purpose and Scope of the Share Buyback Program

The primary objectives behind this share buyback program are twofold: to reduce overall share capital and to fulfill the obligations linked to ISS's share-based incentive plans. This strategic move reflects the company's proactive approach in managing its finances, providing a clear signal to investors about its financial health and commitment to shareholder returns.

Financial Commitment to the Share Buyback Initiative

ISS is set to repurchase shares for a maximum total consideration of DKK 3,000 million. This figure encompasses approximately DKK 1,250 million tied to the completed first tranche of the buyback, demonstrating ISS's robust liquidity position. The initiative will unfold over a span of twelve months, starting from 20 February 2025 and extending to 13 February 2026 at the latest, ensuring ample opportunity for strategic repurchases.

Recent Transactions Under the Buyback Program

In line with the program's objectives, ISS A/S has successfully executed a series of transactions that highlight its commitment to the share buyback scheme. The details of the transactions are as follows:

  • Accumulated, last announcement: 10,048,933 shares, average purchase price DKK 175.43, transaction value DKK 1,762,838,608.
  • On 06 October 2025, 74,770 shares were bought at an average price of DKK 198.01, totaling DKK 14,805,006.
  • On 07 October 2025, 61,000 shares with an average purchase price of DKK 198.44 resulted in a transaction value of DKK 12,104,718.
  • On 08 October 2025, 39,002 shares were repurchased at a price of DKK 200.12, amounting to DKK 7,805,205.
  • On 09 October 2025, 37,000 shares were acquired at DKK 202.00, with a total value of DKK 7,474,044.
  • On 10 October 2025, 39,000 shares were repurchased at an average price of DKK 203.38, resulting in a purchase value of DKK 7,931,777.
  • Accumulated under the program: 10,299,705 shares, average price DKK 176.02, total transaction value DKK 1,812,959,359.

With these proactive measures, ISS A/S now holds 9,397,784 treasury shares, effectively representing 5.39% of its total share capital, a significant step in capital management.

Investor and Media Relations

For those interested in learning more about ISS and its financial strategies, the company encourages inquiries. Michael Vitfell-Rasmussen, the Head of Group Investor Relations, can be contacted at +45 53 53 87 25, or reach out to Anne Sophie Riis, Senior Investor Relations Manager, at +45 30 52 94 68. For media inquiries, Charlotte Holm, the Head of External Communication, is available at +45 41 76 19 89.

About ISS A/S

As a global leader in providing workplace and facility service solutions, ISS A/S is dedicated to enhancing the engagement and well-being of employees across various sectors. With a workforce of over 325,000 employees, referred to as “placemakers,” ISS is committed to minimizing environmental impacts while maintaining high property standards. In the previous fiscal year, the group reported impressive revenues of DKK 83.7 billion, showcasing its substantial market presence.

For further information about ISS Group, visit www.issworld.com.

Frequently Asked Questions

What is the purpose of the ISS A/S share buyback program?

The share buyback program aims to reduce share capital and fulfill obligations related to share-based incentive plans.

How much is ISS A/S planning to spend on the buyback?

ISS plans to repurchase shares for up to DKK 3,000 million over a period of twelve months.

When is the share buyback program expected to conclude?

The program is expected to conclude by 13 February 2026 at the latest.

What percentage of shares does ISS A/S currently own as treasury shares?

ISS A/S owns 5.39% of its total share capital as treasury shares.

Who can be contacted for investor inquiries about ISS A/S?

Michael Vitfell-Rasmussen and Anne Sophie Riis are available for investor inquiries regarding ISS A/S.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Revitalizing ER+ Breast Cancer with Palazestrant and Ribociclib

Updated Category News Views 264

Promising Advances in Breast Cancer Treatment Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a pioneering biopharmaceutical company specializing in breast cancer therapies, recently revealed compelling data from its Phase 1b/2 trial examining the effects of palazestrant combined with ribociclib in patients battling estrogen...

Continue Reading
Recent Share Transactions by Danske Bank Management Team

Updated Category News Views 135

Recent Share Transactions by Danske Bank Management Team Danske Bank A/S has been making headlines with its ongoing share buy-back program, a key strategic move aimed at enhancing shareholder value. As management and executives involve themselves in these transactions, it is essential to stay informed about their actions, which are a reflection of the company's health and...

Continue Reading
Purpose Legal's PurposeXi: AI-Driven Legal Revolution or Just Hype?

Updated Category News Views 171

Purpose Legal just unveiled PurposeXi™ on February 17, 2026—this shiny new tool aims to revolutionize the legal landscape by integrating AI across the board. Traders are raising eyebrows because while they tout speed and efficiency, we've seen this play before. Remember when tech made bold claims but left investors hanging when reality hit? Well, buckle up....

Continue Reading
PowerBank's Vision for Dominating the Data Center Industry

Updated Category News Views 138

Insight into the Data Center Market PowerBank Corporation (NASDAQ: SUUN) is stepping into the spotlight as a key player in the rapidly expanding data center market. The company is poised to leverage its expertise in energy infrastructure development and asset ownership to address the rising demand for power supply in data centers. Projections suggest that the data center...

Continue Reading
Exploring the Promising Landscape of Adenosine Antagonists

Updated Category News Views 156

Introduction to Adenosine Antagonists Adenosine antagonists represent a fascinating domain in medical research, particularly due to their potential implications across various therapeutic areas. As these compounds inhibit adenosine—a nucleoside that governs essential physiological functions—they may revolutionize treatment options for diseases such as cancer,...

Continue Reading